Our vision is to improve the treatment of severe diseases. Working with the medicines of the future we focus on oncology.

Research and Development

Human HealthOasmia is development the next generation of drugs with focus on oncology.

Further reading »

About Oasmia

Animal HealthOasmia is a pharmaceutical company in Uppsala, Sweden with one approved product in Russia and one conditionally approved in the USA.

Further reading »

The Share

Latest News

Oasmia Has Submitted a Marketing Authorization Application to the European Medicines Agency for Its Lead Cancer Product Apealea® (Paclical®)

February 8 2016
Uppsala, Sweden – February 8, 2016. Oasmia Pharmaceutical AB (NASDAQ: OASM) today announced the submission of a marketing authorization application (MAA) to the European Medicines Agency (EMA) for its lead cancer product Apealea (also known as Paclical). Apealea is a new formulation of paclitaxel in nanoparticular form based Oasmia’s XR-17 technology.
Further reading »

Oasmia Pharmaceutical to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference and BIO CEO & Investor Conference in New Yor

February 4 2016
Further reading »

Oasmia Pharmaceutical Makes Key Hires; Strengthens Organizational Structure Entering Commercial Phase

February 2 2016
Further reading »